

HPTN 035

**Phase II/IIb Safety and Effectiveness Study
of the Vaginal Microbicides
BufferGel and 0.5% PRO 2000/5 Gel (P)
for the Prevention of HIV Infection in Women**

MTN Annual Meeting

March 2007

Primary Objectives

- ◆ **To evaluate the safety of BufferGel and 0.5% PRO 2000/5 Gel (P) when applied intravaginally by women at risk for sexually-transmitted HIV infection**
- ◆ **To estimate the effectiveness of BufferGel and 0.5% PRO 2000/5 Gel (P) in preventing HIV infection**

Study Treatment Regimen

- ◆ All participants receive ongoing HIV risk reduction counseling, condoms, and diagnosis and treatment of sexually transmitted diseases
- ◆ Participants in the three gel arms additionally receive gel supplies and instructions to insert a single dose of gel intravaginally up to 60 minutes before each act of vaginal sex, using single-use, pre-filled applicators

Participant Accrual

- ◆ Phase II accrual target: 800
- ◆ Phase II actual accrual (final): 799

- ◆ Phase II/IIb accrual target: 3100
- ◆ Phase II/IIb actual accrual: 2389
as of 9 March 2006

- ◆ Accrual is planned to be completed by the
end of July 2007

Accrual By Site

	<u>Target</u>	<u>Actual to Date</u>
◆ Durban	704	552
◆ Lilongwe	600	516
◆ Harare-Chitungwiza	483	273
◆ Blantyre	443	323
◆ Lusaka	320	180

Accrual completed in the following sites:

◆ Hlabisa	350	350
◆ Philadelphia	200	200

Baseline Characteristics

- ◆ Mean age = 26.9 (SD = 6.7 years)
- ◆ 58% married
- ◆ 64% living with husband/partner
- ◆ 96% with one sex partner in the last three months
- ◆ Mean number of vaginal sex acts in last week = 2.7 (SD = 2.4)
- ◆ 65% of vaginal sex acts in last week involved a condom

Follow-up Visits

	Retention Rate	Mean Days Between Target and Actual Visit Dates
Month 3	93%	-1.6
Month 6	91%	-0.9
Month 9	92%	-1.0
Month 12	90%	-1.2

Adherence to Gel Use

	# Last Sex Acts	% Gel Use Overall	% Gel Use With Condom	% Gel Use Without Condom
Oct-05	120	73%	84	47
Jan-06	393	72%	80	53
Apr-06	900	74%	82	57
Jul-06	1375	75%	82	60
Oct-06	2001	77%	83	64
Jan-07	2970	78%	83	68
Mar-07	3923	79%	83	71

Gel adherence by site by March 07

	<u>%gel use overall</u>	<u>% gel without condom</u>
◆ Zimbabwe	91	84
◆ Lusaka	80	81
◆ Hlabisa	83	72
◆ Durban	80	72
◆ Lilongwe	72	71
◆ Blantyre	82	63
◆ Philadelphia	79	59

% Gel Use in the Past Week

	All Visits		Excl Visits on Hold or After Seroconversion	
	Per Act	Per Woman	Per Act	Per Woman
With Condom	81	77	84	80
Without Condom	75	76	81	81
Overall	79	80	83	84

Pregnancy

- ◆ **205 pregnancies to date in 197 participants, among 2082 participants who have completed at least one follow-up visit**
- ◆ **Pregnancy rate = 13.6 per 100 w-years**
- ◆ **Outcomes of 97 pregnancies to date:**
 - **51 full term live births**
 - **3 premature live births**
 - **18 therapeutic/elective abortion**
 - **31 spontaneous abortions**
 - **5 fetal deaths/still births**

Adverse Events

	Definitely Related	Probably Related	Possibly Related	Probably Not Related	Not Related	Total
Mild	4	29	400	2964	2345	5746
Moderate	0	3	123	1270	1702	3099
Severe	0	0	2	46	98	146
Life-threatening	0	0	0	1	6	7
Death	0	0	0	0	1	1
Total	4	32	525	4281	4152	8999

Note: Sums include 4 mild and 1 moderate adverse events not shown in table with missing relationship assessment.

DSMB Reviews

- ◆ **DSMB reviews to date:**
 - Oct 2005 (<2% follow-up accumulated)
 - Jan 2006 (4% follow-up accumulated)
 - Oct 2006 (10% follow-up accumulated)
 - Mar 2007 (33% follow-up accumulated)
- ◆ **DSMB complimented the 035 team for the high quality of study conduct**
- ◆ **No concerns raised – DSMB decision: continue the trial without change**
- ◆ **Study well on track - Next review: June 2007**